Improvements In pCR, EFS With Or Without Pembrolizumab Linked To Biomarkers In Patients With High-Risk Early TNBC, Analysis Finds

Cancer Network (12/11, Sava) reports, “Improvements in pathologic complete response (pCR) and event-free survival (EFS) with or without pembrolizumab (Keytruda) were associated with biomarkers such as T-cell inflamed 18-gene expression profiles in patients with high-risk early triple-negative breast cancer (TNBC), according to exploratory analysis data from the phase 3 KEYNOTE-522 study.” Researchers found that tumor mutational burden “also correlated with improved EFS in the pembrolizumab plus chemotherapy arm...but not in the placebo plus chemotherapy arm.” The findings were presented at the San Antonio Breast Cancer Symposium. Also reporting is OncLive (12/11, Sava).